Molecular Insight Pharmaceuticals, Inc. 4
4 · Molecular Insight Pharmaceuticals, Inc. · Filed Feb 5, 2007
Insider Transaction Report
Form 4
Babich John W
DirectorPresident, CEO and CSO
Transactions
- Conversion
Common Stock
2007-02-01+27,702→ 27,702 total - Conversion
Series A Convertible Preferred Stock
2007-02-01−641→ 0 total→ Common Stock (27,702 underlying)
Footnotes (4)
- [F1]The reporting person held 641 shares of Series A Convertible Preferred Stock. In connection with the issuer's IPO, the Series A Convertible Preferred Stock automatically converted into 27,702 shares of Common Stock, which number of shares includes accrued and unpaid dividends on the Series A Preferred Stock as of February 1, 2007.
- [F2]Immediately.
- [F3]Not applicable.
- [F4]The reporting person holds Employee Stock Options to purchase 594,167 shares of the Common Stock, as previously reported on Form 3.